StreetAlpha
13F holdings · Q3 2026

Kynam Capital Management

Princeton, NJ · files as Kynam Capital Management, LP
Know the moment Kynam Capital Management filesYou follow Kynam Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1907884

Kynam Capital Management reported 34 stocks worth $1.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LEGN (10.1%), CLDX (9.1%) and SNDX (8.5%). Compared with Q2 2026, the fund opened new positions in SRZN, XENE and EVMN, added to LEGN, SNDX and COGT, trimmed CLDX, PCVX and VRDN and sold out of INSM and CADL.

Latest filing: what Kynam Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new8 added6 trimmed2 sold outBought about $235M · sold about $56M
New 4
Added 8
See all 8 →
Trimmed 6
See all 6 →
Sold out 2

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.8B−0.2% vs last quarter
Stocks held344 new · 2 sold out
Top 5 weight42.9%fairly concentrated
Turnover16%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
LEGN
Legend Biotech Corp
$182M10.1%9.2M+6.2M (+205%)4 of 8
2
CLDX
Celldex Therapeutics Inc
$164M9.1%5.1M−257K (−5%)8 of 8
3
SNDX
Syndax Pharmaceuticals Inc
$153M8.5%8.2M+100K (+1%)8 of 8
4
PCVX
Vaxcyte Inc
$148M8.2%2.6M−314K (−11%)8 of 8
5
VRDN
Viridian Therapeutics Inc
$127M7.0%6.1M−306K (−5%)8 of 8
6
COGT
Cogent Biosciences Inc
$121M6.7%3.8M+125K (+3%)8 of 8
7
TVTX
Travere Therapeutics Inc
$118M6.5%2MNo change8 of 8
8
URGN
Urogen Pharma Ltd
$98.9M5.5%2.4MNo change6 of 8
9
VERA
Vera Therapeutics Inc
$96.9M5.4%3M+110K (+4%)8 of 8
10
BEAM
Beam Therapeutics Inc
$96.2M5.3%3.9M+1.1M (+38%)8 of 8
🔒 24 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
INSM
Insmed Inc
$10.7M100K
CADL
Candel Therapeutics Inc
$996K97K

Reported value

last 8 quarters
$1.5BQ4 '24
$1.2BQ1 '25
$929MQ2 '25
$1.3BQ3 '25
$1.5BQ4 '25
$1.6BQ1 '26
$1.8BQ2 '26
$1.8BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Kynam Capital Management 13F FAQ

What does Kynam Capital Management own?

Kynam Capital Management reported 34 stocks worth $1.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LEGN (10.1%), CLDX (9.1%) and SNDX (8.5%). The table above lists every position in the filing (the top 10 without an account).

What did Kynam Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 8 added to, 6 trimmed and 2 sold out. New positions include SRZN, XENE and EVMN. It sold all of INSM and CADL.

When will Kynam Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Kynam Capital Management's portfolio worth?

The Q3 2026 filing reports $1.8B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.